Abivax (ABVX) Total Liabilities (2021 - 2026)

Abivax's Total Liabilities history runs 6 years deep, the most recent figure standing at $137.6 million for Q1 2026.

• In Q1 2026, Total Liabilities changed N/A year-over-year to $137.6 million; the TTM figure through Mar 2026 stood at $137.6 million (changed N/A YoY), while the FY2025 annual figure was $150.3 million, down 14.56% from the prior year.
• Total Liabilities was $137.6 million for Q1 2026 at Abivax, down from $150.3 million in the prior quarter.
• In the past five years, Total Liabilities ranged from a high of $175.9 million in Q4 2024 to a low of $40.2 million in Q4 2023.
• Historically, Total Liabilities has averaged $114.1 million across 5 years, with a median of $137.6 million in 2026.
• The sharpest annual moves came in 2023 and 2024: Total Liabilities plunged 39.66% in 2023, then surged 337.71% in 2024.
• A 5-year view of Total Liabilities shows it stood at $66.6 million in 2022, then slumped by 39.66% to $40.2 million in 2023, then soared by 337.71% to $175.9 million in 2024, then retreated by 14.56% to $150.3 million in 2025, then decreased by 8.46% to $137.6 million in 2026.
• The last three Total Liabilities figures came in at $137.6 million (Q1 2026), $150.3 million (Q4 2025), and $175.9 million (Q4 2024), per Business Quant data.